Latest News and Press Releases
Want to stay updated on the latest news?
-
Biosplice Announces First Patient Dosed in Phase 2 Trial of Cirtuvivint for Advanced Soft-Tissue Sarcomas
-
All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a...
-
- Experienced biopharma professional focused on drug product development Munich, Germany - June 11, 2024 - Thermosome, a drug development company focused on targeted tumor therapies, today...
-
A peer-reviewed study compared optical genome mapping (OGM) to classical cytogenetic techniques used for analysis of solid tumor cancer samples.
-
Valo Therapeutics Announces Regulatory Approval to Expand Phase I Immuno-oncology Trial into Sarcoma
HELSINKI, Finland, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer, announces it has received approval from Germany’s...
-
Leveraging the transformative potential of TSL-based tumor targeting Supporting the progress of Thermosome's clinical candidate THE001 Munich, Germany – September 19, 2023 – Thermosome, a drug...
-
SANTA ANA, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous,...
-
New York, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, and the University of Copenhagen announced...
-
SANTA ANA, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of natural killer cell...
-
SANTA ANA, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...